

BC Cancer Protocol Summary for Palliative Therapy of Extensive Stage Small Cell Lung Cancer (SCLC) with Oral Etoposide

Protocol Code: LUSCPOE
Tumour Group: Lung
Contact Physician: Dr. Christopher Lee

ELIGIBILITY:

- Extensive stage SCLC in patients refusing or unsuitable for combination chemotherapy
- Relapsed SCLC after prior chemotherapy with disease-free interval > 3 months

TESTS:

- Baseline: CBC & differential, platelets
- Before each treatment: CBC & differential, platelets

PREMEDICATIONS:

- See antiemetic guidelines for non-emetogenic chemotherapy (see protocol SCNAUSEA). Antiemetics are not usually required. Prescribe according to patient specific symptoms.

TREATMENT:

| Drug | Dose | BC Cancer Administration Guidelines |
|-----------|-----------------------|-------------------------------------|
| Etoposide | 50 mg PO BID x 7 days | PO |

- Repeat every 21 days x 4-6 cycles

DOSE MODIFICATIONS:

1. Hematology

| ANC (x 10 ⁹ /L) | | Platelets (x 10 ⁹ /L) | Etoposide dose |
|------------------------------|-----|----------------------------------|----------------|
| Greater than or equal to 2.0 | and | Greater than or equal to 100 | 100% |
| Less than 2.0 | or | Less than 100 | Delay |

2. Neutropenic Sepsis: reassess subsequent doses

PRECAUTIONS:

1. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

Contact Dr. Christopher Lee or tumor group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

REFERENCES: